Welcome to our dedicated page for Stoneridge news (Ticker: $SRI), a resource for investors and traders seeking the latest updates and insights on Stoneridge stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Stoneridge's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Stoneridge's position in the market.
Stoneridge, Inc. reported Q1 2024 results with sales of $239.2 million, gross profit of $48.4 million, and operating income of $0.3 million. The company maintained its full-year 2024 guidance with sales of $990.0 million - $1,010.0 million, gross margin of 22.0% - 22.75%, and EPS of $0.30 - $0.40. Despite some challenges like warranty-related expenses impacting Q1 results, Stoneridge is focused on cost reduction and improving profitability through operational efficiency.